Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00807053 · ClinicalTrials.gov registry record · Phase 2
Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)
A Phase 2 study of Rhinitis, Allergic, Seasonal, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 480
- Enrollment target
- 20
- Study locations
NCT00807053 is a Phase 2 study of Rhinitis, Allergic, Seasonal that has completed, run by AstraZeneca. The registered enrollment target is 480 participants, below the 699-participant average among 3 other Rhinitis, Allergic, Seasonal trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00807053, a Phase 2 study of Rhinitis, Allergic, Seasonal, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 480 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to demonstrate the efficacy of ciclesonide HFA, applied as a nasal aerosol once daily, in patients with SAR. The secondary objectives are to evaluate Quality-of-Life and safety.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ciclesonide HFA
Study Locations (20)
California
- Altana/Nycomed - Mission Viejo
- Altana/Nycomed - Orange
- Altana/Nycomed - San Diego
Georgia
- Altana/Nycomed - Gainsville
- Altana/Nycomed - Savannah
- Altana/Nycomed - Stockbridge
Colorado
- Altana/Nycomed - Colorado Springs
- Altana/Nycomed - Denver
Nebraska
- Altana/Nycomed - Lincoln
- Altana/Nycomed - Papillion
New Jersey
- Altana/Nycomed - Skillman
- Altana/Nycomed - West Brick
Oregon
- Altana/Nycomed - Ashland
- Altana/Nycomed - Medford
Indiana
- Altana/Nycomed - Indianapolis
Kansas
- Altana/Nycomed - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2007-04 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00807053
The ClinicalTrials.gov registry entry for NCT00807053 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 699-participant average among 3 other Rhinitis, Allergic, Seasonal trials with a reported enrollment target (31% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rhinitis, Allergic, Seasonal appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00807053 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Georgia, Colorado.
Frequently Asked Questions
What is clinical trial NCT00807053 about?
NCT00807053 is a clinical study titled "Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)". The primary objective of this study is to demonstrate the efficacy of ciclesonide HFA, applied as a nasal aerosol once daily, in patients with SAR. The secondary objectives are to evaluate Quality-of-Life and safety.
What is the current status of trial NCT00807053?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 480 participants. The study started on 2007-04. Estimated completion is 2007-07.
What conditions does trial NCT00807053 study?
This clinical trial studies the following conditions: Rhinitis, Allergic, Seasonal.
What interventions are being tested in trial NCT00807053?
The interventions under investigation include: Placebo (DRUG), Ciclesonide HFA (DRUG).
Who is sponsoring clinical trial NCT00807053?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00807053 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rhinitis, Allergic, Seasonal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine
COMPLETED · Phase 4
-
To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)
COMPLETED · Phase 3
-
A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.